FDA clears new biomarker assays for early Alzheimer’s detection
Roche has received US Food and Drug Administration 510 clearance for additional cerebrospinal fluid assays for Alzheimer’s disease , supporting timely diagnosis and treatment decision-making.
They join the Elecsys beta-amyloid CSF II and Elecsys phospho-tau CSF assays that received FDA 510 clearance in 2022,"An early and accurate diagnosis can help patients, caregivers and physicians determine a path forward, and the Elecsys CSF assays support diagnosis at early disease stages, when treatment is most effective," Brad Moore, president and CEO of Roche Diagnostics North America, said in a statement.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Supreme Court clears way for redrawing of Louisiana congressional map to include 2nd majority-Black districtThe appeal from Louisiana Republicans had been put on hold while the Supreme Court considered a challenge to Alabama's congressional voting bounds.
続きを読む »
NYC congestion pricing plan clears final federal hurdle“Congestion pricing will reduce traffic in our crowded downtown, improve air quality and provide critical resources to the MTA,' New York Governor Kathy Hochul said in a statement.
続きを読む »
FDA approves 1st treatment that can grow back hair for teens with severe alopecia areataMarking a historic first, the FDA has approved an alopecia treatment for kids 12 and over.
続きを読む »
Hydration nation: Clients clamor for IV therapy on demand even though it’s not FDA-approvedAre IV therapy 'bars' and stations worth all the hype? Fox News Digital spoke to multiple experts about the benefits and risks of these on-demand hydration facilities.
続きを読む »
Dublin family celebrates FDA approval of gene therapy for Duchenne developed in Central Oh'It is huge. It’s going to change the course of this disease,' said Dublin mom Amber Nisley. 'I mean, it truly is a game changer. This has never happened before
続きを読む »